Clinical Trial Update: R Retreatment in 1st Relapsed DLBCL [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 retreatment study using rituximab in patients with first-relapsed diffuse large B-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Shanghai Jiao Tong University School of Medicine | Conditions: Lymphomas | Phase 2 | Status: UNKNOWN